Related Experiment Video
Updated: May 26, 2025
02:47
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
1.3K
RNA therapeutics in cardiovascular medicine
Tulsi Ram Damase1, John P Cooke
1Center for RNA Therapeutics, Department of Cardiovascular Sciences, Houston Methodist Academic Institute, Houston, Texas, USA.
Current Opinion in Cardiology
|February 25, 2025
Summary
RNA therapeutics, including antisense oligomers and siRNA, are emerging as a fourth pillar of pharmacotherapy. These RNA drugs show promise for treating cardiovascular diseases and are rapidly advancing in development.
Area of Science:
- Pharmacotherapy
- Molecular Medicine
- Cardiovascular Therapeutics
Background:
- RNA therapeutics gained prominence with mRNA vaccines for SARS-CoV-2.
- Antisense oligomers (ASOs) and small interfering RNA (siRNA) drugs, predating the pandemic, modulate mRNA expression for disease amelioration.
- RNA therapeutics are poised to become the fourth pillar of pharmacotherapy with broad applications.
Purpose of the Study:
- To review approved RNA therapies for cardiovascular diseases.
- To highlight RNA-based drugs currently under clinical evaluation for cardiovascular disorders.
Main Methods:
- Review of FDA-approved ASO and siRNA drugs for cardiovascular conditions.
- Analysis of ongoing clinical trials for novel RNA-based cardiovascular therapies.
Main Results:
- Several ASO and siRNA drugs are FDA-approved for cardiovascular diseases.
- Multiple RNA-based therapies, like Zodasiran targeting ANGPTL3 for LDL reduction, are in clinical trials.
Conclusions:
- RNA drugs offer advantages in sequence choice, design speed, and synthesis.
- Rapid development, broad applications, and lower cost are anticipated for RNA therapeutics.
- RNA therapies represent a significant advancement in treating cardiovascular diseases.
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
437
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
437
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
370
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
370
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
126
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
126
01:16Antianginal Drugs: Nitrates and β-Blockers
495
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
495
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K